Smart chemo: new drug aims to hit HER-2 cancers harder

NCT ID NCT05861895

Recruiting now Disease control Sponsor: HighField Biopharmaceuticals Corporation Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial is testing a new drug called HF158K1 in 84 adults with advanced solid tumors that have HER-2 protein. The drug is a form of chemotherapy wrapped in a fat bubble that carries a targeting molecule to seek out HER-2 cancer cells. The main goals are to check safety, find the right dose, and see early signs of tumor shrinkage.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: HF158K1 (a liposome form of doxorubicin with a HER2-targeting antibody fragment)
What this could lead to: If it works, this could point toward a more targeted chemotherapy for HER-2 positive cancers, potentially reducing side effects.
What could go wrong: This is a very early Phase 1 trial with only 84 people, focused on safety and dosing. It may not show strong anti-tumor effects, and side effects could be significant.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SOLID TUMORS, ADULT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SOLID TUMORS, ADULT

Contacts and locations

Locations

Mary Crowley Cancer Research
RECRUITING

Dallas, Texas, 75241, United States
Sun Yat-sen University Cancer Center
RECRUITING

Guangzhou, Guangdong, 510060, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.